Palliative & End-of-Life Distress

This report summarises what Blossom’s database shows about psychedelic-assisted therapy for distress at the end of life, and what it does not show. The short version: this is the indication where the modern field began, and it produced some of its most striking and durable results. It is also a small, old, and methodologically fragile evidence base that has not advanced to the confirmatory trials it needs, and no psychedelic is approved for this use anywhere. The famous findings and the serious limitations are both real, and an honest reading holds them together.

A note before the evidence

This page is a research summary, not medical advice, and nothing here is a treatment recommendation. Every compound discussed is investigational for end-of-life distress; none is approved for it. Distress at the end of life is treatable through established palliative and psychological care, and decisions about that care belong with a qualified clinical team. If you or someone you love is struggling, a palliative care service or mental-health professional is the right first port of call.

A word on the numbers. Blossom tracks 186 papers and 53 trials tagged to this topic, and those counts appear on this page. The tag is leaky: it pulls in general-depression studies, near-death and mechanism work, provider-attitude surveys, history pieces and reviews, so the genuinely end-of-life-specific clinical core is much smaller, on the order of a dozen modern trials enrolling perhaps 140 randomised patients in total. Read the counts as a measure of how much has been written, not as a tally of completed end-of-life treatments.

What "end-of-life distress" means

Distress at the end of life is more than sadness. It encompasses clinical depression and anxiety, but also demoralisation, hopelessness, loss of meaning and dignity, and the specific fear of dying, what clinicians call existential or spiritual distress. It is common and under-treated. A meta-analysis of 94 interview-based studies found roughly a third of people in oncological and palliative settings meet criteria for a mood disorder[1]Lancet Oncology meta-analysis (2011), and the WHO estimates 56.8 million people need palliative care each year, with only about 14% receiving it[2]WHO palliative care fact sheet. Conventional antidepressants help some people but act too slowly for those with a short prognosis, and they were never designed for existential fear. That gap is the unmet need this research targets.

Why psychedelics were tried here first

The logic is distinctive. Most psychiatric drugs aim to suppress symptoms day by day; the psychedelic approach pairs a single, carefully prepared and supervised high-dose session with psychotherapy, aiming to occasion an experience that changes a person’s relationship to their own death. Patients in these trials often describe a shift from terror and isolation to acceptance and connection, frequently framed in terms of a mystical or transcendent experience. Whether that is a specific drug effect or a profound placebo response is exactly the question the trials struggle to answer, but the clinical target, a person’s stance toward dying, is unusual and is why this field began in the hospice and the cancer ward rather than the psychiatric clinic.

The landmark trials: psilocybin in cancer

The modern evidence base rests on two trials published on the same day in 2016. The Johns Hopkins study randomised 51 patients with life-threatening cancer in a double-blind crossover design, comparing a very low placebo-like dose against a high dose; at six-month follow-up around 80% still showed clinically significant decreases in depressed mood and anxiety[3]J. Psychopharmacology, Griffiths/JHU (2016). The NYU study randomised 29 cancer patients to single-dose psilocybin or niacin (an active placebo), both with psychotherapy, and found rapid, substantial and sustained reductions in anxiety and depression out to 6.5 months[4]J. Psychopharmacology, Ross/NYU (2016). Both were preceded by a smaller 12-patient pilot that established safety and a positive trend[5]Arch. Gen. Psychiatry, Grob (2011).

What makes these results remarkable for psychiatry is not just their size but their persistence from a single dose. A long-term follow-up of the NYU cohort re-assessed survivors at a mean of 3.2 and 4.5 years and found roughly 60 to 80% still met criteria for an antidepressant or anxiolytic response[6]J. Psychopharmacology, Agin-Liebes (2020), with most attributing positive, lasting life change to the experience. A separate analysis found reductions in suicidal ideation and in loss of meaning appearing within hours and holding for years[7]ACS Pharmacol. Transl. Sci. (2021). For a field where most treatments fade in weeks, durability of this kind is the headline.

The asterisks, stated plainly

The qualifications matter as much as the results. The samples are tiny: the entire modern randomised base is around 140 patients. The designs are hard to blind, a high dose of psilocybin or LSD is unmistakable, and both 2016 trials used crossover or active-placebo comparators that cannot hide which arm a patient is in. Because the intensity of the subjective experience also predicts who improves, expectancy and the drug effect are tangled together. Pooled analyses are encouraging but built on the same small studies: a meta-analysis of five trials found psilocybin superior to placebo for end-of-life trait anxiety at six months (Hedges’ g around −0.84)[8]Psychiatry Investigation meta-analysis (2021), and a broader meta-analysis of nine psychedelic-therapy RCTs reported a large between-groups effect (Hedges’ g 1.21)[9]J. Psychoactive Drugs meta-analysis (2020), while noting the same small-sample, blinding and heterogeneity limits.

Two further cautions. Trials select for psychologically and physically robust volunteers, excluding active suicidality, a personal or family history of psychosis or bipolar disorder, and serious cardiac instability, so the sickest and most distressed are often screened out. And no Phase 3, adequately powered, registrational trial exists in this indication. A decade after the landmark studies, the confirmatory evidence that would move psilocybin from "promising" to "proven" for end-of-life distress has not been produced.

Beyond psilocybin: LSD, ketamine and MDMA

Psilocybin dominates, but it is not alone. LSD has the longest history, reaching back to 1960s work with dying patients, and its modern revival is a 2014 active-placebo pilot in 12 patients that found anxiety reductions sustained for 12 months[10]J. Nervous & Mental Disease, Gasser (2014), supported by a larger 2023 Phase II trial (n=42), though that study mixed life-threatening-illness with general anxiety[11]Biological Psychiatry, LSD Phase II (2023). Ketamine offers something different, rapid antidepressant action when time is short: an open-label palliative trial reported 70% response by day 8[12]Cancers, intranasal ketamine (2023), but the cancer evidence is open-label or retrospective, short-lived, and in one pilot null on depression. MDMA rests on a single randomised pilot that missed its primary endpoint (p=0.056)[13]Scientific Reports, MDMA pilot (2020). Each of these is earlier and thinner than the psilocybin story, and should be read that way.

Demoralisation, grief and special populations

A strand of work targets distress beyond classic depression and anxiety. Psilocybin-assisted group therapy reduced demoralisation in older long-term AIDS survivors in an open-label pilot[14]eClinicalMedicine, Anderson (2020), and a hospice pilot found reduced demoralisation even as patients’ illness progressed[15]BMJ Supportive & Palliative Care (2025). Group models in cancer patients with major depression have shown sharp symptom reductions with a two-year durability follow-up[16]Cancer, 2-year follow-up (2025), and trials in prolonged grief and caregiver distress are under way. These are mostly small, open-label and feasibility-stage, but they widen the question from "does this treat depression?" to "can a supported experience ease the broader suffering of dying and loss?"

Safety in a fragile population

On the evidence so far, supervised psychedelic sessions in carefully screened, medically supported patients have a reassuring safety record: serious adverse events are rare across the trials, and an individual-patient-data meta-analysis found psychedelic therapy reduced suicidality, with acute elevations uncommon[17]J. Clinical Psychiatry, IPD meta-analysis (2022). That should be read in context. These are intensive, hours-long experiences delivered with two therapists in a controlled setting, with cardiovascular monitoring and exclusion of higher-risk patients. Transient anxiety, blood-pressure rises and challenging experiences do occur, and the safety profile of a fully supervised trial says little about unsupervised use. In a population that is already vulnerable, the supervision is not an optional extra; it is part of the treatment.

Access, ethics and the law

No psychedelic is approved for end-of-life distress anywhere. They remain investigational, available through clinical trials or, in limited places, compassionate-access schemes. Even Australia’s 2023 reform, which lets authorised psychiatrists prescribe psilocybin, applies only to treatment-resistant depression, not end-of-life distress[18]Australian TGA rescheduling (2023). This creates a genuine ethical tension that the field openly debates: dying patients have the strongest possible claim to try a promising treatment and the least time to wait for evidence, yet they are also among the most vulnerable to hype, to financial exploitation, and to consenting under the pressure of a terminal prognosis. "Right to try" arguments are powerful here and also need guardrails.

Reading this honestly

So where does end-of-life distress sit? It is the field’s origin story and the home of its most durable, most humane-sounding results, a single supported session that, in small trials, lifted depression and the fear of death and kept lifting it for years. That is genuinely moving, and it should not be waved away. But it is built on a handful of tiny, hard-to-blind studies that have not been confirmed at scale, and the gap between the strength of the claims and the strength of the evidence is wider here than almost anywhere else in psychedelic medicine. The honest position refuses both the cynicism that dismisses a real and repeatedly observed effect and the enthusiasm that treats a decade-old pilot literature as settled. For people facing the end of life, the most truthful thing the evidence supports is hope held carefully, a promising approach that deserves rigorous testing, not a proven cure.